86/100BIDEXX Laboratories stock forecast 2026–2030What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for IDEXX Laboratories is 716.67, 1.8% above the current price of 704.23. Their targets range from 700.00 to 740.00.
Of the 8 firms that rated IDEXX Laboratories in the past 12 months, 5 rate it buy or strong buy, 3 hold and 0 sell or strong sell (each firm at its latest rating): a Buy consensus.
Analysts' 1-year price targets range from 700.00 to 740.00, with an average of 716.67.
| Buy | 5 | |
| Hold | 3 | |
| Sell | 0 |
12-month price target
| Highest target | 740.00 |
| Average target | 716.67 |
| Lowest target | 700.00 |
| Current price | 704.23 |
IDEXX Laboratories price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Have analysts recently raised or lowered their IDEXX Laboratories price target and rating?
How analysts rate IDEXX Laboratories, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
5 of 8 firms rate it buy now, against 6 of 9 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
IDEXX Laboratories analyst upgrades, downgrades and price targets
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 3 Nov 2026 | UBS Andrea Alfonso | Reiterated · Neutral | 627.00 → 700.00 | +11.6% | 671.64 |
| 27 Oct 2026 | UBS | Reiterated · Neutral | 620.00 → 627.00 | +1.1% | 562.47 |
| 16 Oct 2026 | Goldman Sachs Matt Dellatorre | — | 740.00 | — | 547.18 |
| 11 Aug 2026 | Barclays Glen Santangelo | Reiterated · Overweight | 800.00 → 710.00 | -11.3% | 595.76 |
| 27 Jul 2026 | UBS | Reiterated · Neutral | 640.00 → 620.00 | -3.1% | 559.86 |
| 28 Apr 2026 | UBS Andrea Alfonso | Reiterated · Neutral | 730.00 → 640.00 | -12.3% | 569.17 |
| 9 Feb 2026 | Piper Sandler | Reiterated · Neutral | 750.00 | — | 644.61 |
| 5 Feb 2026 | Barclays Glen Santangelo | Reiterated · Overweight | 850.00 → 800.00 | -5.9% | 642.94 |
| 3 Feb 2026 | UBS Andrea Alfonso | Reiterated · Neutral | 750.00 → 730.00 | -2.7% | 639.60 |
| 3 Feb 2026 | BTIG | Reiterated · Buy | 830.00 → 800.00 | -3.6% | 639.60 |
| 8 Dec 2025 | Barclays Glen Santangelo | — | 850.00 | — | 706.65 |
IDEXX Laboratories EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect IDEXX Laboratories's EPS to grow 13.6% a year until 2028. Over the last 5 years it grew 14.3% a year, and over the last 3 years 17.7%.
Analysts expect IDEXX Laboratories's revenue to grow 9.5% a year until 2028, about as fast as over the last 5 years (9.7% a year) and the last 3 years (8.5%).
Revenue
EPS
Does IDEXX Laboratories beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 6.5% off the result, either way, and their revenue estimate 1.5%, over the last 12 quarters.
- EPS beats
- 100 / 135
- Revenue beats
- 90 / 120
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +6.5%
- Since
- February 1993
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2 Nov 2026 | 3.73 | 3.96 | +6.2% | 1.19B | 1.21B | +1.9% |
| Q2 FY2026 | 4 Aug 2026 | 3.94 | 4.27 | +8.4% | 1.20B | 1.22B | +1.4% |
| Q1 FY2026 | 5 May 2026 | 3.41 | 3.47 | +1.8% | 1.12B | 1.14B | +2.0% |
| Q4 FY2025 | 2 Feb 2026 | 2.93 | 3.08 | +5.1% | 1.07B | 1.09B | +1.7% |
| Q3 FY2025 | 3 Nov 2025 | 3.14 | 3.40 | +8.3% | 1.07B | 1.11B | +3.0% |
| Q2 FY2025 | 4 Aug 2025 | 3.28 | 3.63 | +10.7% | 1.06B | 1.11B | +4.4% |
| Q1 FY2025 | 1 May 2025 | 2.85 | 2.96 | +3.9% | 997.10M | 998.43M | +0.1% |
| Q4 FY2024 | 3 Feb 2025 | 2.39 | 2.62 | +9.6% | 935.15M | 954.29M | +2.0% |
| Q3 FY2024 | 31 Oct 2024 | 2.68 | 2.80 | +4.5% | 980.32M | 975.54M | -0.5% |
| Q2 FY2024 | 6 Aug 2024 | 2.88 | 3.02 | +4.9% | 1.01B | 1.00B | -0.3% |
| Q1 FY2024 | 1 May 2024 | 2.67 | 2.81 | +5.2% | 964.41M | 964.10M | -0.0% |
| Q4 FY2023 | 5 Feb 2024 | 2.12 | 2.32 | +9.4% | 891.25M | 901.60M | +1.2% |
IDEXX Laboratories stock price 2026–2030: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If IDEXX Laboratories's earnings keep growing at the 13.6% a year analysts expect to FY2028, it would earn about 24.72 a share in FY2030. At the P/E it has traded at over the last five years (38.4 to 54.6) that is 948.99 to 1,349.20 a share, or 1,196.81 at its average P/E of 48.4. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 14.91 | 572.54 | 722.04 | 813.99 |
| FY2027 | 16.84 | 646.62 | 815.47 | 919.31 |
| FY2028 | 19.16 | 735.44 | 927.49 | 1,045.59 |
| FY2029 (extrapolated) | 21.76 | 835.42 | 1,053.58 | 1,187.73 |
| FY2030 (extrapolated) | 24.72 | 948.99 | 1,196.81 | 1,349.20 |
Each year's EPS is the analysts' consensus to FY2028; the years after grow 13.6% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (38.4, 48.4, 54.6).
Is IDEXX Laboratories stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
IDEXX Laboratories's P/E of 47.5 is around the middle of its 5-year range (33.6 to 74.6, median 48.5). It is in line with its own history. Buyers pay about the usual price for each point of growth: a PEG of 3.5 on expected growth against 3.4 on its median P/E and past five years' growth. At its usual P/E (48.5 × EPS of 14.83), IDEXX Laboratories's fair value is 719.99, close to the price of 704.23. Its forward P/E, on the consensus for FY2026, is 47.2.
Fair value is the usual (median) P/E of the last five years times the earnings per share of the last twelve months; the ends of the bar are the same earnings at its lowest and highest P/E of those years (33.6 and 74.6). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 47.49
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 48.55
- Five-year P/E range
- 33.6 – 74.6
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 47.22
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 3.49
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +1.8%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 35.850 | 71.4258Price 35.85193 | +99.2% | |
| 29.050 | 56.2634Price 29.0596 | +93.7% | |
| 241.000 | 464.49205Price 241.00627 | +92.7% | |
| 123.590 | 237.24178Price 123.59297 | +92.0% | |
| 161.400 | 305.52159Price 161.40396 | +89.3% | |
| 157.460 | 297.58169Price 157.46471 | +89.0% | |
| 217.560 | 405.38304Price 217.56507 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.